Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBanerjee, Susana
dc.contributor.authorGonzalez-Martin, Antonio
dc.contributor.authorHarter, Philipp
dc.contributor.authorLorusso, Domenica
dc.contributor.authorMoore, Kathleen N
dc.contributor.authorOaknin benzaquen, Ana Mazaltob
dc.date.accessioned2021-09-20T10:03:20Z
dc.date.available2021-09-20T10:03:20Z
dc.date.issued2020-12-11
dc.identifier.citationBanerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open. 2020 Dec 11;5:e001110.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/6331
dc.descriptionPARP inhibitors; Advanced ovarian cancer
dc.description.abstractPoly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesESMO Open;5
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectOvaris - Càncer -Tractament
dc.subjectInhibidors enzimàtics - Ús terapèutic
dc.subject.meshOvarian Neoplasms
dc.subject.meshPoly(ADP-ribose) Polymerase Inhibitors
dc.titleFirst-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/esmoopen-2020-001110
dc.subject.decsneoplasias ováricas
dc.subject.decsinhibidores de poli(ADP-ribosa) polimerasas
dc.relation.publishversionhttps://doi.org/10.1136/esmoopen-2020-001110
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Banerjee S] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Gonzalez-Martin A] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Harter P] Department of Gynaecology and Gynaecological Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany. [Lorusso D] Scientific Directorate and Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy. [Moore KN] Stephenson Cancer Center, University of Oklahoma, Norman, Oklahoma, USA. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid33310779
dc.identifier.wos000608044000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record